Index RUT
P/E -
EPS (ttm) -1.23
Insider Own 18.73%
Shs Outstand 333.93M
Perf Week 0.85%
Market Cap 596.07M
Forward P/E -
EPS next Y -0.76
Insider Trans 0.10%
Shs Float 271.39M
Perf Month -22.73%
Enterprise Value 289.52M
PEG -
EPS next Q -0.28
Inst Own 64.20%
Short Float 35.66%
Perf Quarter -45.91%
Income -375.36M
P/S 2.80
EPS this Y 12.10%
Inst Trans -0.46%
Short Ratio 7.08
Perf Half Y -72.11%
Sales 212.68M
P/B 0.78
EPS next Y 32.36%
ROA -40.88%
Short Interest 96.78M
Perf YTD -75.88%
Book/sh 2.30
P/C 1.65
EPS next 5Y 45.16%
ROE -51.85%
52W High 12.51 -85.73%
Perf Year -78.85%
Cash/sh 1.08
P/FCF -
EPS past 3/5Y 16.82% 4.17%
ROIC -46.22%
52W Low 1.64 8.94%
Perf 3Y -85.74%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y - -
Gross Margin 11.01%
Volatility 8.74% 6.96%
Perf 5Y -94.09%
Dividend TTM -
EV/Sales 1.36
EPS Y/Y TTM 32.07%
Oper. Margin -187.50%
ATR (14) 0.16
Perf 10Y -80.56%
Dividend Ex-Date -
Quick Ratio 3.64
Sales Y/Y TTM 11070.12%
Profit Margin -176.49%
RSI (14) 44.17
Recom 2.08
Dividend Gr. 3/5Y - -
Current Ratio 4.18
EPS Q/Q 15.22%
SMA20 -3.71%
Beta 0.84
Target Price 10.00
Payout -
Debt/Eq 0.07
Sales Q/Q 6798.46%
SMA50 -11.45%
Rel Volume 3.09
Prev Close 2.01
Employees 838
LT Debt/Eq 0.06
Earnings May 08 AMC
SMA200 -67.92%
Avg Volume 13.68M
Price 1.78
IPO Sep 01, 2009
Option/Short Yes / Yes
EPS/Sales Surpr. -48.94% -40.12%
Trades
Volume 16,423,026
Change -11.19%
Date
Action
Analyst
Rating Change
Price Target Change
Today Downgrade
Goldman
Neutral → Sell
$1
May-16-25 Downgrade
UBS
Buy → Neutral
$2
May-12-25 Downgrade
Truist
Buy → Hold
May-09-25 Downgrade
Citizens JMP
Mkt Outperform → Mkt Perform
Oct-24-24 Initiated
UBS
Buy
$17
Jul-29-24 Downgrade
Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated
Goldman
Buy
$12
Sep-18-23 Reiterated
Barclays
Overweight
$40 → $18
May-30-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade
Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade
Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated
Guggenheim
Neutral
Aug-18-22 Resumed
Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade
Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed
Cowen
Outperform
Jun-10-21 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade
Stifel
Buy → Hold
May-19-21 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Show Previous Ratings
Today 07:30AM
Jul-14-25 07:30AM
Jul-10-25 04:01PM
Jul-06-25 06:47AM
Jun-29-25 08:36AM
06:57PM
Loading…
Jun-27-25 06:57PM
12:00PM
Jun-24-25 01:36PM
09:00AM
Jun-23-25 04:05PM
Jun-20-25 11:56AM
11:56AM
Jun-19-25 01:03PM
Jun-16-25 02:00PM
Jun-13-25 05:45AM
10:00AM
Loading…
Jun-12-25 10:00AM
Jun-10-25 06:35PM
08:45AM
Jun-06-25 05:45AM
Jun-03-25 01:54PM
Jun-02-25 10:06AM
09:29AM
May-29-25 12:03PM
May-28-25 12:02PM
09:12AM
May-23-25 05:10PM
May-22-25 10:13PM
05:31PM
05:05PM
May-21-25 09:11AM
04:48AM
Loading…
04:48AM
May-20-25 09:10PM
04:36PM
05:45AM
May-17-25 08:00AM
May-16-25 06:39PM
(Motley Fool) -5.68%
+10.24%
05:30PM
May-15-25 05:14AM
May-13-25 09:00AM
08:53AM
May-11-25 11:15AM
May-09-25 07:56PM
(Business Wire) -44.79%
+10.29%
11:33AM
11:03AM
08:06AM
03:40AM
May-08-25 05:30PM
04:23PM
(Associated Press Finance)
04:01PM
May-07-25 05:20PM
May-06-25 08:10AM
03:15AM
May-02-25 04:01PM
Apr-30-25 05:14AM
Apr-23-25 04:15PM
06:10AM
Apr-22-25 07:09AM
Apr-19-25 10:00AM
Apr-18-25 05:44PM
05:30PM
Apr-16-25 10:02AM
Apr-14-25 10:05AM
Apr-09-25 09:45AM
Apr-07-25 08:09AM
Apr-03-25 12:07PM
Mar-28-25 04:30PM
Mar-25-25 05:43PM
Mar-22-25 01:56PM
11:05AM
Mar-21-25 05:15PM
Mar-17-25 03:46PM
Mar-12-25 10:15AM
Mar-04-25 07:36AM
Feb-28-25 02:37AM
Feb-27-25 05:25PM
04:29PM
(Associated Press Finance)
04:01PM
Feb-21-25 05:15PM
Feb-20-25 10:01AM
Feb-18-25 04:01PM
Feb-12-25 05:30PM
Feb-10-25 07:00AM
Jan-30-25 07:30AM
Jan-29-25 08:30AM
Jan-27-25 04:31AM
Jan-20-25 03:10PM
Jan-18-25 06:50PM
Jan-17-25 05:00PM
Jan-09-25 04:20AM
Jan-02-25 07:03PM
03:24AM
Dec-20-24 05:00PM
Dec-19-24 04:02AM
Dec-17-24 05:29AM
Dec-12-24 10:00AM
Dec-07-24 11:08AM
Nov-27-24 06:30AM
Nov-26-24 04:01PM
Nov-23-24 11:35AM
10:31AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kirby Daniel Gordon Chief Commercial Officer Jun 05 '25 Buy 1.84 30,000 55,200 30,000 Jun 06 04:05 PM Puri Raj K. Chief Regulatory Officer Jun 02 '25 Option Exercise 0.00 5,469 0 212,321 Jun 04 04:51 PM Vogt Frederick G Interim CEO & General Counsel Jun 02 '25 Option Exercise 0.00 52,085 0 426,731 Jun 04 04:50 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 02 '25 Option Exercise 0.00 12,695 0 105,608 Jun 04 04:49 PM BILINSKY IGOR Chief Operating Officer Jun 02 '25 Option Exercise 0.00 12,305 0 99,883 Jun 04 04:47 PM Bellemin Jean-Marc Chief Financial Officer Jun 02 '25 Option Exercise 0.00 8,789 0 64,993 Jun 04 04:46 PM Puri Raj K. Chief Regulatory Officer May 23 '25 Buy 1.74 5,600 9,743 206,852 May 27 04:06 PM Vogt Frederick G Interim CEO & General Counsel May 14 '25 Buy 1.69 25,000 42,250 374,646 May 16 04:05 PM Puri Raj K. Chief Regulatory Officer Mar 14 '25 Option Exercise 0.00 8,334 0 203,761 Mar 18 08:30 PM Bellemin Jean-Marc Chief Financial Officer Mar 03 '25 Option Exercise 0.00 58,590 0 87,938 Mar 05 08:33 PM BILINSKY IGOR Chief Operating Officer Mar 03 '25 Option Exercise 0.00 62,106 0 120,880 Mar 05 08:32 PM Vogt Frederick G Interim CEO & General Counsel Mar 03 '25 Option Exercise 0.00 223,943 0 445,059 Mar 05 08:32 PM Puri Raj K. Chief Regulatory Officer Mar 03 '25 Option Exercise 0.00 59,999 0 215,411 Mar 05 08:31 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 03 '25 Option Exercise 0.00 62,497 0 126,383 Mar 05 08:30 PM Vogt Frederick G Interim CEO & General Counsel Jan 14 '25 Option Exercise 0.00 20,835 0 231,071 Jan 16 06:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 14 '25 Option Exercise 0.00 2,813 0 65,464 Jan 16 06:00 PM BILINSKY IGOR Chief Operating Officer Jan 14 '25 Option Exercise 0.00 2,813 0 60,352 Jan 16 05:59 PM Puri Raj K. Chief Regulatory Officer Dec 16 '24 Option Exercise 0.00 8,334 0 159,171 Dec 18 05:15 PM Vogt Frederick G Interim CEO & General Counsel Dec 02 '24 Option Exercise 0.00 10,417 0 214,662 Dec 04 04:31 PM BILINSKY IGOR Chief Operating Officer Dec 02 '24 Option Exercise 0.00 3,516 0 59,323 Dec 04 04:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '24 Option Exercise 0.00 3,906 0 64,633 Dec 04 04:30 PM Maynard Ryan D Director Nov 12 '24 Option Exercise 7.45 50,000 372,500 57,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Sale 10.06 50,000 503,000 7,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Proposed Sale 10.06 50,000 503,104 Nov 12 07:11 PM Vogt Frederick G Interim CEO & General Counsel Oct 14 '24 Option Exercise 0.00 20,834 0 213,096 Oct 16 06:33 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 14 '24 Option Exercise 0.00 2,813 0 62,155 Oct 16 06:32 PM BILINSKY IGOR Chief Operating Officer Oct 14 '24 Option Exercise 0.00 2,813 0 57,235 Oct 16 06:30 PM Vogt Frederick G Interim CEO & General Counsel Sep 03 '24 Option Exercise 0.00 57,292 0 212,175 Sep 05 07:56 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 03 '24 Option Exercise 0.00 27,345 0 71,233 Sep 05 07:54 PM BILINSKY IGOR Chief Operating Officer Sep 03 '24 Option Exercise 0.00 26,954 0 66,313 Sep 05 07:53 PM Bellemin Jean-Marc Chief Financial Officer Sep 03 '24 Option Exercise 0.00 23,438 0 41,239 Sep 05 07:52 PM